Small molecule · Inhibitor of KIT (c-Kit) receptor tyrosine kinase (KIT) · developed by GlaxoSmithKline
Velzatinib is an orally bioavailable small molecule that binds and inhibits multiple mutated forms of the KIT receptor tyrosine kinase. It is being studied in gastrointestinal neoplasms, including gastrointestinal stromal tumor (GIST), and metastatic cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05489237 | Phase 1 | Gastrointestinal Neoplasms | Active not recruiting | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Digestive System DiseaseGastrointestinal DiseasesGastrointestinal NeoplasmsGastrointestinal Stromal Tumor (GIST)Metastatic Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →